parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in salivary acinar cells	0.75
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 12993

FAM107A in dopamine neurons, braak-0.49 (p 0.186) → +0.14 (p 0.723)receipt 13001
FAM107A in astrocytes, braak-0.09 (p 0.812) → -0.90 (p 0.001)receipt 13000

receipt 13001: FAM107A in dopamine neurons, braak

power: full sample -0.16 (p 0.526, n 18), 95% CI -0.58 to +0.33. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.31 (p 0.207, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.36 (p 0.140, n 18). could be the mix.
skeptic: leave-one-out range -0.28 to -0.04, sign flips 0; without severely affected donors -0.16 (p 0.526, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for FAM107A in dopamine neurons.

case closed: nothing better to follow up.

receipt 13000: FAM107A in astrocytes, braak

power: full sample -0.36 (p 0.142, n 18), 95% CI -0.71 to +0.13. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.39 (p 0.114, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.45 (p 0.059, n 18). could be the mix.
skeptic: leave-one-out range -0.48 to -0.27, sign flips 0; without severely affected donors -0.36 (p 0.142, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for FAM107A in astrocytes.

case closed: nothing better to follow up.

loading the receipts